SentoClone International AB Significantly Strengthens its Global Patent Portfolio Covering its Clinical Stage Sentinel Node-derived CD4 T-cell Cancer Therapy
STOCKHOLM, June 5, 2013 /PRNewswire/ –
New patents granted in Japan, the USA and Europe
SentoClone International AB announced today that it has been granted additional
patents in Japan, the US and Europe further reinforcing the global protection of its
proprietary SentoClone(R) technology, an active patient specific cellular immunotherapy
against cancer based on the ex vivo cultivation and activation of CD4+ T-cells. The
technology has advanced to Phase II clinical trials following Phase I and pilot studies in
patients with colorectal and bladder cancer.
SentoClone International’s chairman Pingsheng Hu said, “We are determined to develop
our SentoClone(R) technology as rapidly as possible so that it can become an effective
patient specific cancer therapy without significant side effects for the broad range of
cancer patients worldwide. The recent patents we have been granted in Japan, the US and
Europe means we have very solid IP in all major markets in the field of sentinel node
derived T-cells in cancer therapy. We believe this much stronger patent protection will
allow us to attract development partners so that we can make this novel approach to cancer
therapy available to the many patients globally who could benefit.”
The SentoClone(R) technology builds on a unique approach whereby CD4+ T- helper cells,
highly specific for the patient’s individual tumor, are extracted from the tumor’s
draining lymph node (the sentinel node) and cultivated ex vivo in a GMP production
facility before being returned to the patient via one single infusion. During cultivation,
the T-cells are stimulated with growth factors and re-activated with antigen from the
patient’s individual tumor. Once returned to the patient the T-cells induce effector cells
of the immune system to attack the tumor tissue highly specifically, leaving other tissue
unaffected. Evidence indicates that the technology also generates a powerful long-term
immunologic memory where T-cells are patrolling the body in a process called
To-date more than 200 patients with a range of cancers have been treated using this
unique approach with no significant side effects being reported. The safety profile,
combined with its synergistic mode of action, suggest that SentoClone(R) technology could
be an ideal addition to current or upcoming cancer treatment regimens.
The recent patents granted to SentoClone covering its Sentinel node-derived CD4 T-cell
cancer therapy are as follows:
- In Japan, patent 5244610, titled "Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy in cancer" covers the process of ex vivo cultivation and activation of CD4+ T-cells. It is the Company's second patent granted in Japan during 2013. - In Europe, patent EP 1966370B1, titled "Method for obtaining T-lymphocytes" covers the use in cancer immunotherapy of T-cells derived from metastasis-draining lymph nodes ("metinel nodes"). It is the Company's third European patent and is presently being validated in the major European countries. - In the USA, patent US 8211425B2, titled "Method for treating disseminated cancer" is the Company's sixth patent granted in the US and covers the use of metinel node T-cells in cancer immunotherapy.
SentoClone International holds 24 international patents, including these new grants,
within eight families. The portfolio comprises six patents in the USA, three patents in
Europe and two patents in Japan. In addition, SentoClone International’s Chinese parent
company Jiangsu Sinorda Biomedicine Co. holds patents for the Chinese market.
SentoClone International is based in Sweden and in China and aims to become the global
leader in autologous active cellular immunotherapy against cancer based on the ex vivo
cultivation and activation of T-cells. The SentoClone(R) technology was invented at
Sweden’s Karolinska University Hospital in Stockholm and the early clinical trials with
this unique technology have been taking place in Sweden. Since 2010 the company is a
subsidiary of Jiangsu Sinorda Biomedicine Co. of China.
About Jiangsu Sinorda Biomedicine Co.
Jiangsu Sinorda Biomedicine, located in Taicang City, Jiangsu Province, close to
Shangha is a medical services company focusing on immunotherapy and diagnostics. It
operates through propriatory laboratories in large hospitals in China under Chinese
regulations. Sinorda develops new drugs and diagnostic kits primarily targeting cancer but
also in other disease areas. R&D is performed jointly with SentoClone International and
other collaborating companies.